Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 9/20 | 0.58 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.58 |
| ▸ | PLOD2 | O00469 | 2/20 | 0.55 |
| ▸ | PLOD3 | O60568 | 2/20 | 0.55 |
| ▸ | PLOD1 | Q02809 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | MPO | P05164 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL6118414 | 1.00 | GSK3B (0.58) | GSK3BPTPN1PLOD2PLOD3PLOD1 | |
| SCHEMBL84572 | 0.98 | GSK3B (0.60) | GSK3BPTPN1PLOD2PLOD3PLOD1 | |
| Hydrochloric Acid SCHEMBL899290 | 0.95 | GSK3B (0.58) | GSK3BPTPN1PLOD2PLOD3PLOD1 | |
| Bromide SCHEMBL2773952 | 0.93 | GSK3B (0.56) | GSK3BPTPN1PLOD2PLOD3PLOD1 | |
| Bromide SCHEMBL9203773 | 0.88 | GSK3B (0.63) | GSK3BPTPN1PLOD2PLOD3PLOD1 | |
| SCHEMBL7428121 | 0.81 | PLOD2 (0.60) | GSK3BPTPN1PLOD2PLOD3PLOD1 | |
| Pyridine SCHEMBL18321129 | 0.81 | GSK3B (0.76) | GSK3BPTPN1PLOD2PLOD3PLOD1 | |
| SCHEMBL7265428 | 0.80 | PLOD2 (0.53) | GSK3BPTPN1PLOD2PLOD3PLOD1 | |
| SCHEMBL205280 | 0.80 | GSK3B (0.80) | GSK3BPTPN1 | |
| SCHEMBL15988710 | 0.78 | CYP2C19 (0.61) | PLOD2PLOD3PLOD1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 429 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743455-A1 | SARM1 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2026-05-20 | — | — | EP | disclosed |
| CN-121586713-A | Quinoline derivatives and pharmaceutical compositions thereof for the treatment of diseases | 百济神州(苏州)生物科技有限公司 | 2026-02-27 | — | — | CN | disclosed |
| US-20250388582-A1 | NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF | ILDONG PHARMACEUTICAL CO LTD (KR) | 2025-12-25 | — | — | US | disclosed |
| EP-4556476-A1 | NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF | Ildong Pharmaceutical Co., Ltd. (KR) | 2025-05-21 | — | — | EP | disclosed |
| EP-4139286-B1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AG (DE) | 2025-02-26 | — | — | EP | disclosed |
| WO-2025021943-A1 | QUINAZOLINONE, BENZOXAZINONE AND BENZOXAZEPINONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | NEURALIS (BE) | 2025-01-30 | — | — | WO | disclosed |
| WO-2025021217-A1 | QUINOLINE DERIVATIVES AND PHARMARCEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASE | BEIGENE SWITZERLAND GMBH (CH) | 2025-01-30 | — | — | WO | disclosed |
| WO-2025012296-A1 | SARM1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2025-01-16 | — | — | WO | disclosed |
| CN-118930543-A | Tricyclic compounds, pharmaceutical compositions and uses thereof | 深圳众格生物科技有限公司 | 2024-11-12 | — | — | CN | disclosed |
| CN-118284604-A | Fused heterocycles as RIPK1 inhibitors | 比西切姆有限公司 | 2024-07-02 | — | — | CN | disclosed |
| EP-0306300-A2 | Pyrrolo(1,2-a)imidazole and imidazo(1,2-a)pyridine derivatives and their use as 5-lipoxygenase pathway inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 1989-03-08 | — | — | EP | disclosed |
| US-4788194-A | CARDIOTONIC AGENTS, HYPOTENSIVE AGENTS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-11-29 | — | — | US | disclosed |
| US-4751310-A | Inhibition of the 5-lipoxygenase pathway | SMITHKLINE BECKMAN CORPORATION (US) | 1988-06-14 | — | — | US | disclosed |
| WO-1988001169-A1 | INHIBITION OF INTERLEUKIN-1 PRODUCTION BY MONOCYTES AND/OR MACROPHAGES | SMITHKLINE BECKMAN CORPORATION (US) | 1988-02-25 | — | — | WO | disclosed |
| US-4719218-A | ENZYME INHIBITORS | SMITHKLINE BECKMAN CORPORATION (US) | 1988-01-12 | — | — | US | disclosed |
| US-4716164-A | CARDIOTONIC, HYPOTENSIVE | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-12-29 | — | — | US | disclosed |
| EP-0231622-A2 | Inhibition of the 5-lipoxygenase pathway | SMITHKLINE BEECHAM CORPORATION (US) | 1987-08-12 | — | — | EP | disclosed |
| US-4558045-A | CARDIOTONIC AND HYPOTENSIVE ACTIVITY | IMPERIAL CHEMICAL INDUSTRIES, PLC (GB) | 1985-12-10 | — | — | US | disclosed |
| US-4489073-A | HYPOTENSIVE AND CARDIOTONIC AGENTS | IMPERIAL CHEMICAL INDUSTRIES, PLC (GB) | 1984-12-18 | — | — | US | disclosed |
| EP-0085227-A1 | Thiadiazine derivatives, and pharmaceutical compositions containing them | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1983-08-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388582-A1 | NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF | GBA1, PIKFYVE, MAN2B1 | GSK3B 3174/4885PTPN1 862/4885PLOD2 4232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.